• CardioExcyte 96

    结合阻抗与类MEA记录
  • CardioExcyte 96

    用于心脏安全筛选
  • CardioExcyte 96

    下一代非标记细胞分析
  • CardioExcyte 96

    直观的数据分析&心律失常检测
  • CardioExcyte 96

    提供可用于成像的透明板

Cardiomyocytes - "Impedance and EFP recordings of Cor.4U cells using Nanion’s CardioExcyte 96"

Icon CE   CardioExcyte 96 Application Note   logo pdf   (1.3 MB)
Cells were kindly provided by Ncardia.  

 Summary:

Cardiomyocytes derived from human inducedpluripotent stem cells (hiPSCs) are gaining interest in cardiac safety screening. Given their relative abundance, availability, ease of use and standardized production, they are likely to provide a viable alternative to acutely isolated cardiomyocytes to assess the pro-arrythmic potentials of drug candidates. Although automated patch clamp can provide excellent information about the effects of compounds on cardiac ion channels and possible effects on the cardiac action potential, other techniques, such as impedance, also provide crucial and complementary information about complex physiological parameters such as beat rate, amplitude and duration. The CardioExcyte 96 is a new hybrid screening tool combining impedance (cell contractility) and extracellular field potential (EFP) recordings. These measurements are non-invasive, label-free and have a temporal resolution of 1 ms. The recordings are made from cells within a network thus providing a physiologically relevant environment for measuring drug-induced changes in beat parameters. This hybrid technology addresses the lack of easy-to-use high-throughput screening for in-vitro assays, and permits the reliable investigation of short- and long-term pharmacological effects. Here we present data recorded on the CardioExcyte 96 using Cor.4U hiPSCs from Ncardia. The effects of the compounds blebbistatin, E4031 and nifedipine on the impedance and EFP signals are shown.

返回总览

 

 

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok